Table 1.
Baseline Characteristics for Patients Diagnosed With ATTR-CA (N = 2,141)
| Baseline characteristics | |
| Age, y | 76.5 ± 8.4 |
| Male | 1,885 (88.0) |
| Ethnicity | |
| White | 1,759 (82.2) |
| Afro-Caribbean | 353 (16.5) |
| Asian | 21 (1.0) |
| Other | 8 (0.4) |
| Genotypes | |
| wtATTR | 1,573 (73.5) |
| p.(V142I) hATTR | 292 (13.6) |
| Non-p.(V142I) hATTR | 276 (12.9) |
| Heart failure severity | |
| NYHA functional class | |
| I | 282 (13.2) |
| II | 1,368 (63.9) |
| III | 333 (15.6) |
| IV | 13 (0.6) |
| Missing | 145 |
| 6MWT distance, m | 347 (250-427) |
| 6MWT, % predicted | 71.2 ± 26.8 |
| Systolic blood pressure, mm Hg | 125.8 ± 17.3 |
| Diastolic blood pressure, mm Hg | 75.0 ± 10.2 |
| Heart rate, beats/min | 72.0 ± 12.8 |
| Blood biomarkers | |
| NAC stage | |
| 1 | 1,095 (51.1) |
| 2 | 732 (34.2) |
| 3 | 314 (14.7) |
| NT-proBNP, ng/L | 2,581 (1,315-4,581) |
| eGFR, mL/min/1.73 m2 | 60 (47-73) |
| Hemoglobin, g/L | 138 (127-148) |
| Serum total bilirubin, μmol/L | 13 (9-18) |
| Alanine transaminase, IU/L | 25 (19-33) |
| Alkaline phosphatase, IU/L | 90 (71-119) |
| GGT, IU/L | 67 (32-134) |
| Echocardiographic parameters | |
| IVSd, mm | 16.8 ± 2.5 |
| PWTd, mm | 16.3 ± 3.6 |
| LVEF, % | 49.0 ± 10.7 |
| Longitudinal strain, % | –11.2 ± 3.9 |
| E/e′ | 16.5 ± 7.2 |
Values are mean ± SD, n (%), n, or median (Q1-Q3).
ATTR-CA = transthyretin cardiac amyloidosis; eGFR = estimated glomerular filtration rate; GGT = gamma-glutamyl transferase; hATTR-CA = hereditary transthyretin cardiac amyloidosis; IVSd = interventricular septum in diastole; LVEF = left ventricular ejection fraction; NAC = National Amyloidosis Centre; NT-proBNP = N-terminal pro–B-type natriuretic peptide; PWTd = posterior wall thickness in diastole; wtATTR-CA = wild-type transthyretin cardiac amyloidosis.